News
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Technology will soon make it possible to develop cheap, widely accessible psychoactive substances that are not harmful in the ...
Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...
Kate Farms has launched high-protein plant-based shakes to tackle "critical nutrition gaps" from GLP-1 use, its first product ...
Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...
Ever since Frederiksen took office in Denmark in 2019, the second woman and youngest person ever to become prime minister in ...
There’s no such thing as 'natural Ozempic.' While supplements like psyllium, berberine, and glucomannan are paraded as ...
Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...
New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs for millions of people.
Spain is investigating Novo Nordisk over concerns it may be illegally advertising its weight loss drugs Ozempic and Wegovy ...
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results